Security key
45826J105
Intellia Therapeutics, Inc. - COMMON STOCK (NTLA)
CUSIP: 45826J105
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 101,252,381
- Total 13F value
- $719,981,345
- Share change
- +2,175,080
- Put/Call ratio
- 88%
- SEC-reported price per share
- $7.11
- Number of holders
- 289
- Value change
- +$1,659,582
- Number of buys
- 141
- Number of sells
- 136
- Shares outstanding
- 135,808,632
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
289
Top holders
10
NTLA full security history
Ownership snapshot
Full 13F holder table
Intellia Therapeutics, Inc. SEC filings
Intellia Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of NTLA - Intellia Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
ARK Investment Management...
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
13D/G
Lead comparable stake: 8.2%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 8.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
8.2%
ARK Investment Management LLC
9.2%
VANGUARD GROUP INC
7.5%
STATE STREET CORP
3.8%
MORGAN STANLEY
2.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
8.2%
from 13D/G
|
$126,600,704
10,857,693 shares
|
— | 31 Dec 2024 |
| ARK Investment Management LLC |
13F
Company
|
9.2%
|
$146,174,266
12,536,386 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
7.5%
|
$118,816,017
10,190,053 shares
|
— | 31 Dec 2024 |
| STATE STREET CORP |
13F
Company
|
3.8%
|
$60,698,439
5,205,698 shares
|
— | 31 Dec 2024 |
| MORGAN STANLEY |
13F
Company
|
2.8%
|
$44,477,612
3,814,546 shares
|
— | 31 Dec 2024 |
| REGENERON PHARMACEUTICALS, INC. |
13F
Company
|
2.7%
|
$43,176,922
3,702,995 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
289
Shares
101,252,381
Rows available
289
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
289
Q1 2025 holders
289
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|